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Abstract 
Background: Olfactory (OD) and gustatory (GD) dysfunction have been proven to be a 
typical symptom of SARS-CoV-2 infection. However, their prevalence in different patient 
populations still needs to be clarified. 
Methods: A cross-sectional study was performed from March 27 to April 1 2020 in Northern 
Italy. Physicians administered a survey-based questionnaire to SARS-CoV-2 positive patients 
with the aim of assessing symptoms, focusing on OD and GD. Two groups were studied: 
patients hospitalized at ASST Spedali Civili University Hospital of Brescia (A); home-
quarantined subjects (B). 
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Results: A total of 508 patients were enrolled: 295 in Group A and 213 in Group B. Mean 
age (±SD) was 55±15 years; 56% were men. Overall, OD and GD were present in 56% (95% 
CI 51-60%) and 63% (59-67%) of cases, respectively. In Group A, the prevalence of OD and 
GD was 44% (38-50%) and 52% (46-58%). In Group B, the prevalence of OD and GD was 
72% (65-79%) and 79% (73-84%). In the entire cohort, total loss of olfaction and taste was 
reported in 64% and 60% of cases, respectively. OD and GD occurred as the first symptom in 
10% and 11% of cases; in the remaining cases, they occurred after a mean of 4±3 days 
following the first symptom. At the time of the questionnaire, complete resolution of OD and 
GD was reported in 52% and 55% of cases (mean duration: 9±5 in both). 
Conclusions: OD and GD are more prevalent in home-quarantined subjects, and they are 
independently associated with younger age and female gender.  
 
 
Introduction 
Since December 2019, the SARS-CoV-2 pandemic is placing significant burden on 
healthcare systems and governments. Countries have applied a wide range of large-scale 
infection control policies to respond to the crisis, with variable results. Notwithstanding, 
these policies should be adaptive and evolve according to appropriate evidence. 
In this view, two peculiarities of SARS-CoV-2 should be underlined. Different from SARS-
CoV-1, SARS-CoV-2 is mainly localized in the upper airways and significant viral load 
levels are detectable in both asymptomatic and symptomatic patients.
1,2
 These features are 
expected to cause a higher rate of upper airway complaints, and suggests a potential risk of 
transmission from asymptomatic and mildly symptomatic subjects. In fact, undocumented but 
infectious cases are a critical epidemiological issue and play a vital role in the transmission 
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dynamics of SARS-CoV-2,
3
 leading to the strong need to better identify this subgroup of 
subjects. 
Recent reports on Covid-19 have highlighted a high prevalence of olfactory (OD) and 
gustatory dysfunction (GD).
4-7
 OD in SARS-CoV-2 infected subjects has also been 
demonstrated with olfactometric tests,
7
 and was independently associated with outpatient care 
in a recent study by Yan et al.
8
 
In this view, the precise definition of highly specific symptoms may greatly improve the 
identification of undocumented subjects. However, screening policies should take into 
account the variability of these symptoms according to the characteristics of different patient 
populations. 
The study aims to estimate the different characteristics of OD and GD in hospitalized patients 
and home-quarantined subjects with a nasal/pharyngeal swab positive for SARS-CoV-2 in an 
epidemic area.  
 
Methods 
Study population, setting, and data collection 
Cases with confirmed infection for SARS-CoV-2 were included in a cross-sectional study. 
Only laboratory-confirmed cases (positive by real-time polymerase chain reaction [RT-PCR] 
on a nasal/pharyngeal swab) were included. Serology was not available at the time of the 
study. Data were collected from March 27 to April 1 2020 through a survey-based 
questionnaire on symptoms, focusing on OD and GD (i.e., time of onset, duration, severity, 
characteristics, and relationship with other symptoms). This report followed the 
 A. Grammatica 
 
This article is protected by copyright. All rights reserved. 
 
5 
Strengthening the Reporting of Observational Studies in Epidemiology (STROBE) 
guidelines.
9
 
Inclusion criteria were: 
- signed written informed consent; 
- male or female > 18 years of age; 
- willing and able to participate in the study; 
- positive nasal/pharyngeal swab for SARS-CoV-2 (RT-PCR); 
Exclusion criteria were: 
- legal incapacity or limited legal capacity; 
- medical or psychological condition or situation which in the opinion of the 
investigator would not permit the patient to complete the questionnaire or sign 
informed consent; 
- invasive ventilation; 
- non-invasive ventilation preventing adequate communication; 
- pre-existing chronic anosmia and/or ageusia. 
Enrolled cases included: 
- Group A: patients hospitalized in Covid-19 Units (Pneumology, Internal Medicine, 
Infectious disease, and Emergency) of the ASST Spedali Civili University Hospital 
(Brescia, Italy); 
- Group B: home-quarantined subjects recruited through exponential snowball 
sampling. Each subject provided the contact information of confirmed positive cases 
in his social circle. After specific consent, positivity to nasal/pharyngeal swab for 
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SARS-CoV-2 was confirmed through access to their clinical data or contact with their 
general practitioner. 
Healthcare system policy for nasal/pharyngeal swab for SARS-CoV-2 were defined as: recent 
(less than 14 days) close contact (less than 1 meter for more than 15 minutes and without 
personal protective equipment) with someone who tested positive for SARS-CoV-2 and 
symptoms highly suggestive for Covid-19. The test was repeated within 24-48 hours in case 
of negative results and persistent suspicious symptoms. 
All subjects with positive nasal/pharyngeal swab for SARS-CoV-2 were home-quarantined or 
hospitalized. Factors evaluated for hospitalization included: 
- severe or worsening symptoms; 
- PaO2/FIO2 <350 or PaO2 <75 mmHg or SaO2 <94%; 
- unfavorable home and social conditions; 
- evidence of moderate/severe interstitial pneumonia at chest X-ray, chest computed 
tomography (CT), or chest ultrasound; 
- age >65 years; 
-  presence of significant comorbidities. 
The indication to hospitalization or quarantine was considered as a surrogate marker of full-
blown disease (Group A) or mildly symptomatic clinical presentation (Group B), 
respectively.  
Patients were not informed about the specific study aim to minimize confirmation bias. All 
subjects signed an informed consent form approved by the institutional review board. The 
study was performed following the principles of the Declaration of Helsinki and was 
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approved by the Research Review Board, Ethics Committee, of the ASST Spedali Civili of 
Brescia, Italy (study reference number: NP4037). 
Study Objectives 
The primary objective was the estimate of prevalence and definition of timing of onset, 
resolution, and characteristics of OD and GD in Covid-19 hospitalized and home-quarantined 
subjects. The secondary objective was the assessment of the association of OD/GD with 
patient characteristics, symptoms, and radiological pulmonary alterations. 
Study Definitions 
Hereinafter, when we refer to our cohort, we intend all individuals included in the study 
(group A+B) as “cases”, those hospitalized (group A) as “patients”, and those home 
quarantined (group B) as “subjects”.  
Coexisting conditions were ascertained from physician documentation and questionnaire 
administration. Symptoms presenting as a consequence of a known pharmacological side 
effect or oxygen therapy were excluded from evaluation.  
Chest-X ray was performed in all hospitalized patients (Group A). Since March 4
 
2020 in our 
hospital a chest x-ray scoring system was introduced for semi-quantitative assessment of lung 
disease in Covid–19. It ranked the pulmonary involvement on a 0-to-18-point severity scale 
(18 being the most severe) according to the extent and characteristics of lung infiltrates.
10
 
  
 
 
 A. Grammatica 
 
This article is protected by copyright. All rights reserved. 
 
8 
Specimen Collection and Testing 
Clinical samples for SARS-CoV-2 diagnostic testing were obtained according to WHO 
guidelines.
11
 The nasal/pharyngeal swab was performed using UTM® COPAN 
FLOQSwabs®. SARS-CoV-2 nucleic acids were detected by RT-PCR using GeneFinder™ 
COVID-19 Plus RealAmp Kit by OSANG Healtcare (Anyang, Republic of Korea), or 
Allplex™ 2019-nCoV Assay by Seegene Inc. (Seoul, Republic of Korea). The two kits have 
comparable diagnostic accuracy. 
Survey-based Questionnaire 
The survey-based questionnaire was precisely defined and administered by a physician. The 
translated version of the questionnaire and data collection form is described in the 
Supplementary Materials. Data were collected in a dedicated database. 
Statistical Analysis 
On the basis of an expected OD prevalence of 30%, we estimated that given a maximum risk 
of type I error of 5%, a sample size of 500 patients would provide an estimate with a 
precision plus or minus 4%.  
The prevalence of OD, GD and their corresponding 95% confidence intervals (CI) were 
calculated according to binomial distributions. The tetrachoric correlation between OD and 
GD was also calculated. Comparisons between group A and B were performed using T-test, 
Mann Whitney, and Chi-squared tests as appropriate. Multivariable logistic regression 
models were used to assess factors related to OD and GD, while a multivariable linear 
regression model was performed to evaluate factors associated with radiologic score. Results 
were expressed in terms of odds ratios and regression coefficients, respectively. The final 
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models included factors associated with outcomes when adjusting for age (bivariable 
analyses). For more details, see the Supplementary Materials. 
 
Results 
Demographic and clinical characteristics 
A total of 575 cases were evaluated; of those, 508 were included in the study. Fifty-six 
patients were excluded due to critical health conditions (i.e., irresponsive, unconscious, and 
with significant respiratory effort), 6 due to pre-existing chronic ageusia or anosmia (5 
undocumented and 1 due to total laryngectomy), 3 due to language barrier, and 2 refused to 
participate in the study.  
Group A included 295 (58%) hospitalized patients and Group B was composed of 213 (42%) 
home-quarantined subjects. Mean lag time between swab and survey, and between symptoms 
onset and survey were 11±8 days and 18±7 days, respectively (Table 1). The mean (±SD) age 
was 55±15 years (range, 18–91); 56% were men. In all, 40% of cases had no significant 
comorbidity. Group A had a significantly higher prevalence of older patients, smokers, and 
comorbidities. Cohort characteristics by Group are summarized in Table 1, S1, and S2. 
Prevalence 
The prevalence of symptoms is detailed in Table 2. In the entire population, OD and GD were 
present in 56% (95% CI 51-60%) and 63% (95% CI 59-67%) of cases, respectively. In Group 
A the prevalence of OD and GD was 44% (95% CI 38-50%) and 52% (95% CI 46-58%), 
respectively. Their prevalence was significantly higher in Group B: 72% (95% CI 65-78%) 
and 79% (95% CI 73-84%), respectively. OD and GD were more prevalent in younger 
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patients, females, non-smokers, and those without comorbidities (Table 3). OD and GD were 
reported as complete loss (anosmia or ageusia) in 64% and 60% of cases, respectively. GD 
without OD was present in 10% of cases.  
 
Onset and duration 
OD and GD developed at the onset in 10% and 11% of cases, respectively; in 5% they were 
the only complaint. The remaining developed the symptom after a mean of 4±3 days. At the 
time of the questionnaire, complete resolution of OD and GD was reported by 56% and 59% 
of cases, with a similar mean duration (9±5 days) (Table 4).  
Associations at multivariable analysis 
At multivariable analyses, older age (10-year age increase, OR 0.76, 95% CI 0.67-0.87, 
p<0.001) and male gender (OR 0.62, 95% CI 0.43-0.91, p=0.015) were associated with a 
decreased risk of OD; while arthromyalgia (OR 1.76, 95% CI 1.21-2.57, p=0.003) and nasal 
congestion (OR 1.62, 95% CI 1.01-2.6, p=0.047) with an increased risk. Similar results were 
found considering GD, demonstrating a negative association with age (OR 0.78, 95% CI 
0.68-0.89, p<0.001) and male gender (OR 0.89, 95% CI 0.33-0.72, p<0.001), and a positive 
association with arthromyalgia (OR 1.85, 95% CI 1.25-2.73, p=0.002) (Table S3). No 
evidence of association between OD/GD and the radiologic score was observed (analysis 
limited to Group A) (Supplementary Materials). 
By network analysis, a strong positive connection was detected between OD and GD. Other 
solid connections were found between diarrhea and nausea, fever and arthromyalgia, and 
nasal congestion and pharyngodynia (Figure 1 and S1 [Supplementary Materials]).  
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Discussion 
The study describes a sample of more than 500 cases with confirmed SARS-CoV-2 infection, 
distinguishing between hospitalized patients and home-quarantined subjects. Overall, the 
prevalence of OD and GD was over 50%. In accordance with recent evidence,
8
 in our series 
both symptoms had a significantly higher prevalence in home-quarantined subjects (72% and 
79%, respectively). These prevalence rates are in line with two recent cross-sectional studies, 
in which the prevalence of OD and GD was 68-86% and 71-89%, respectively.
5,6
 The 
sensitivity (i.e., prevalence) of OD and GD should be weighed against those reported for RT-
PCR (78%), CT (67%), and a combination of both (92%).
12
 Nonetheless, the sensitivity of 
RT-PCR is extremely variable, with significant differences according to the specimen 
analyzed (32% in pharyngeal swabs, 63% in nasal swabs, and 93% in bronchoalveolar lavage 
fluid).
13
 Moreover, even if the sensitivity of CT can reach values of 97% in hospitalized 
patients with full-blown disease, this value dramatically decreased in mildly symptomatic 
patients (61%).
14-16
 Finally, both RT-PCR and CT may be largely impractical in an epidemic 
area, as they would require repetitive large-scale evaluations, thus posing evident logistic and 
cost-related issues. In this setting, OD and GD assessment in the general population could be 
a simple, cost-effective, and reliable screening tool.  
Of note, we demonstrated that the sensitivity is strictly related with the specific population 
analyzed (i.e., hospitalized vs. home-quarantined subjects). This difference is also consistent 
with the distinct case distribution between the two groups, with a higher rate of younger and 
otherwise healthy subjects, females, and non-smokers being under quarantine. Moreover, the 
impairment associated with a severe clinical condition and a decrease in oral intake may have 
reduced the perception of OD and GD in the inpatient setting. In fact, hospitalized patients 
showed a significantly higher rate of dyspnea and a lower rate of flu-like symptoms (i.e., 
headache, arthromyalgia, nasal congestion, pharyngodinia, and ocular discomfort).  
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This finding further reinforces the possible utility of OD and GD in population monitoring. In 
fact, the reliability of OD and GD as biomarker of COVID-19 was higher in younger and 
mildly symptomatic subjects, which represents the fraction of population at a higher risk to 
be under-diagnosed and become active carriers of disease spread. In particular, this 
improvement in diagnosis could be particularly useful during the loosening of lockdown 
policy, when early detection of positive cases in workers is essential to prevent new 
outbreaks. 
All cases with OD and GD reported an acute onset and a significant degree of dysfunction, 
without solid connection with other symptoms suggestive of upper airway infection (i.e., 
pharyngodynia and nasal congestion). OD and GD were strongly correlated and clustered 
separately from other symptoms. These characteristics are indicative of acute sensorineural 
OD and GD, which is particularly uncommon in the general population.  
A growing body of evidence shows that neurotropism is a common feature of 
coronaviruses.
17,18
 Notably, SARS-CoV-1 has been found to enter the brain via the olfactory 
bulb and showed diffuse neuronal death in mice transgenic for human angiotensin-converting 
enzyme 2 (ACE2).
19
 This is an important clue suggesting a similar mechanism in SARS-
CoV-2, while direct proof of neuroinvasion is still not available.
20,21
 Analogous damage to 
the olfactory epithelium and extension to the olfactory bulb has also been described in 
coronavirus-related sensorineural post-viral olfactory dysfunction (PVOD).
22
 However, 
differently from PVOD, in the present cohort patients were younger and experienced OD 
early in the course of the disease, often reporting a sudden onset and gradual, quick recovery. 
The identification of selective GD without OD in 10% of cases is a rarely reported 
occurrence in other diseases of the upper respiratory tract.
23
 This phenomenon may be 
explained by SARS-CoV-2 infection at the level of epithelial cells of the tongue, in which the 
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expression of ACE2 is highly enriched, similarly to what happens in the olfactory 
epithelium.
24,25
  
While various degrees of chronic OD and GD have a non-negligible prevalence in the general 
population,
26,27
 impairment often occurs gradually and the patient frequently does not report 
significant changes in perceptual acuity until the dysfunction becomes severe.
28,29
 
Conversely, acute OD, often associated with hypogeusia or ageusia, is immediately 
recognized and can be associated with a variety of pathologic conditions, in particular acute 
upper respiratory infection, head trauma, toxins, and drugs.
26
 In these cases, acute damage to 
the olfactory epithelium, olfactory fila, and gustatory epithelium can usually be identified by 
adequate anamnesis (i.e., recent head trauma, exposure to toxic inhalants, and new 
medications). Furthermore, upper respiratory infection leading to olfactory and gustatory 
alterations is invariably associated with rhinorrhea and nasal congestion. Conversely, OD 
and/or GD in SARS-CoV-2 infection are weakly connected with nasal congestion and 
therefore suggestive of predominant sensorineural chemosensory dysfunction. Further 
evidence of its neurogenic nature is the high prevalence of GD without other complaints at 
the level of the oral cavity and, in some cases, in the absence of olfactory alterations. In this 
view, OD and GD of sudden onset should be safely considered as highly suggestive of Covid-
19 in endemic areas and call for particular attention. Moreover, subjects with non-specific 
symptoms should be carefully interrogated to identify relatives or close contacts presenting 
OD and/or GD to further upgrade their risk-profile according to this information. This is of 
paramount importance in a context of widespread domiciliary confinement imposed by 
government policies. 
The following strengths and limitations should be highlighted. This report clearly shows the 
different distribution of OD and GD according to distinct populations. All patients were 
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recruited from a specific geographic area and directly interviewed by the authors to minimize 
the risk of selection and reporting biases. On the other side, current policy on the execution of 
nasal/pharyngeal swab in our region may have introduced a selection bias, since positive 
asymptomatic or mildly symptomatic subjects could be largely underrepresented. The 
impossibility to interview patients in critical conditions prevented us from defining the 
prevalence of OD and GD in this group with unfavorable outcome. Recall bias should be also 
considered, although it is likely marginal in view of the short time-span between the 
interview and symptoms onset, and the precision of patient responses. Possible 
misclassification due to the information bias should also be taken into account even if 
minimized by the structure of the interviews and the characteristics of the onset of the 
symptoms. Finally, objective tests or comprehensive questionnaires focusing on evaluation of 
smell and taste were not employed in view of the critical healthcare situation. 
 
Conclusion 
A radical increase in the identification and isolation of currently undocumented infections is 
crucial to fully control SARS-CoV-2 diffusion.
3
 However, maintaining surveillance during a 
pandemic is particularly challenging due to shortages in testing materials and facilities. 
Highly suggestive symptoms such as acute olfactory and gustatory dysfunctions may 
facilitate the identification of infected individuals. However, the prevalence of these 
symptoms should be contextualized in view of their different prevalence in different patient 
populations. 
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Table 1. Demographic and Clinical Characteristics 
  
       
  
Variable 
 
Hospitalized 
 
Home-
quarantined   
  
  
 
 
(Group A) 
 
(Group B) 
 
p-value   
  
 
 
N=295 
 
N=213 
 
Group A vs 
B 
  
  
 
 
     
  
Mean age ± SD (range) - yr 
 
61.9 ± 12.8 (24-
91)  
44.7 ± 12.1 (18-
74)  
p<0.001   
  
 
 
     
  
Gender - no. (%) 
 
     
  
  Male 
 
204 (69.2) 
 
81 (38.0) 
 p<0.001 
  
  Female 
 
91 (30.8) 
 
132 (62.0) 
 
  
  
 
 
     
  
History of smoking - no. (%) 
 
     
  
  No smoker 
 
184 (62.4) 
 
158 (74.2) 
 
p<0.001 
  
  Current smoker [average pack-year] 
 
12 (4.1) [29.4 
p.y.]  
18 (8.4) [7.3 p.y.] 
 
  
  Former smoker [average pack-year] 
 
99 (33.5) [25.4 
p.y.]  
37 (17.4) [15.7 
p.y.]  
  
  
 
 
     
  
Mean lag time swab - survey ± SD (range) - days 
 
6.9 ± 6.1 (1-39) 
 
16.2 ± 7.9 (0-35) 
 
p<0.001   
  
 
  
 
 
  
  
Mean lag time onset of symptoms - survey ± SD (range) 
- days 
 
15.9 ± 6.7 (1-45) 
 
20.9 ± 7.4 (6-45) 
 
p<0.001   
  
 
  
    
  
Major comorbidities - no. (%) 
 
     
  
  Obesity 
 
60 (20.3) 
 
7 (3.3) 
 
p<0.001   
  Hypertension 
 
140 (47.5) 
 
26 (12.2) 
 
p<0.001   
  Cardiac disease 
 
48 (16.3) 
 
4 (1.9) 
 
p<0.001   
  Diabetes mellitus 
 
59 (20) 
 
6 (2.8) 
 
p<0.001   
  Renal disease 
 
11 (3.7) 
 
1 (0.5) 
 
p=0.017   
  Chronic or allergic rhinosinusitis / Asthma 
 
27 (9.2) 
 
26 (12.2) 
 
p=0.267   
  Pulmonary disease 
 
21 (7.1) 
 
2 (0.9) 
 
p=0.001   
  Immunodeficiency # 
 
26 (8.8) 
 
5 (2.3) 
 
p=0.005   
  Others § 
 
59 (11.6) 
 
29 (5.7) 
 
p=0.011   
  
 
 
     
  
Number of comorbidities - no. (%) 
 
     
  
  None 
 
63 (21.3) 
 
142 (66.7) 
 
p<0.001 
  
  1-2 
 
176 (59.7) 
 
62 (29.1) 
 
  
  >2 
 
56 (19.0) 
 
9 (4.2) 
 
  
                 
# Immunodeficiency includes immunosuppressive therapy, recent or current hematological malignancy. 
§ Other comorbidities include history of cancer, hypothyroidism, chronic neurological conditions, liver, and vascular 
diseases. 
Statistical tests were used as appropriate (T-test, Mann Whitney, Chi-squared tests) 
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Table 2. Prevalence of Symptoms in the Series 
  
         
  
Variable 
 
Hospitalized 
 
Home-quarantined 
  
  
  
  
(Group A) 
 
(Group B) 
 
p value   
  
 
N=295 
 
N=213 
 
Group A vs B   
  
         
  
Symptoms - no. (%) 
 
Total First symptom 
 
Total First symptom 
 
Chi-squared test   
  
         
  
  Olfactory dysfunction 
 
130 (44.1) 34 (11.5) 
 
153 (71.8) 18 (8.5) 
 
p<0.001   
  Gustatory dysfunction 
 
153 (51.9) 35 (11.9) 
 
168 (78.9) 22 (10.2) 
 
p<0.001   
  Fever 
 
274 (92.9) 167 (56.6) 
 
181 (85.0) 106 (49.8) 
 
p=0.006   
  Dry cough 
 
190 (64.4) 30 (10.2) 
 
138 (64.8) 28 (13.1) 
 
p=0.995   
  Dyspnea 
 
181 (61.4) 19 (6.4) 
 
73 (34.3) 5 (2.3) 
 
p<0.001   
  Headache 
 
79 (26.8) 10 (3.4) 
 
119 (55.9) 19 (8.9) 
 
p<0.001   
  Asthenia 
 
200 (67.8) 36 (12.2) 
 
152 (71.4) 28 (13.1) 
 
p=0.446   
  Arthromyalgia 
 
114 (38.6) 16 (5.4) 
 
142 (66.7) 32 (15.0) 
 
p<0.001   
  Diarrhea 
 
104 (35.3) 9 (3.1) 
 
67 (31.5) 3 (1.4) 
 
p=0.424   
  Nausea 
 
75 (25.4) 2 (0.7) 
 
39 (18.3) 1 (0.5) 
 
p=0.074   
  Nasal congestion 
 
45 (15.3) 8 (2.7) 
 
69 (32.4) 11 (5.2) 
 
p<0.001   
  Pharyngodynia 
 
41 (13.9) 13 (4.4) 
 
67 (31.5) 16 (7.5) 
 
p<0.001   
  Ocular discomfort 
 
38 (12.9) 4 (1.4) 
 
47 (22.1) 2 (0.9) 
 
p=0.009   
  Syncope 
 
25 (8.5) 3 (1.0) 
 
17 (8.0) 1 (0.5) 
 
p=0.971   
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Table 3. Demographic and Clinical Characteristics according to Olfactory and Gustatory Dysfunction 
  
           
  
Variable 
 
No dysfunction 
 
Olfactory dysfunction 
 
Gustatory dysfunction   
  
  
N=175 
 
N=283 
 
p 
value*  
N=321 
 
p 
value* 
  
  
           
  
Mean age ± SD (range) - yr 
 
59.4 ±15.2 (24-
85)  
52 ± 14.4 (18-
91)  
p<0.00
1  
51.9 ± 14.5 (18-
91)  
p<0.00
1 
  
  
           
  
Gender - no. (%) 
          
  
  Male 
 
121 (23.8) 
 
138 (27.2) 
 
p<0.00
1 
 
155 (30.5) 
 
p<0.00
1 
  
  Female 
 
54 (10.6) 
 
145 (28.5) 
  
166 (32.7) 
 
  
  
           
  
History of smoking - no. (%) 
          
  
  No smoker 
 
112 (22.0) 
 
195 (38.4) 
 
p=0.01
9 
 
223 (43.9) 
 
p=0.03
3 
  
  
Current smoker [average pack-
year]  
6 (1.2) [16.8 
p.y.]  
23 (4.5) [11.4 
p.y.]   
23 (4.5) [12.1 
p.y.]  
  
  
Former smoker [average pack-
year]  
57 (11.2) [26.2 
p.y.]  
65 (12.8) [18.8 
p.y.]   
75 (14.8) [18.4 
p.y.]  
  
  
           
  
Number of comorbidities - no. 
(%)           
  
  None 
 
52 (10.2) 
 
134 (26.4) 
 p<0.00
1 
 
148 (29.1) 
 p=0.00
1 
  
  1-2 
 
99 (19.5) 
 
113 (22.2) 
  
136 (26.8) 
 
  
  >2  
 
24 (4.7) 
 
36 (7.1) 
  
37 (7.3) 
 
  
  
           
  
Clinical management 
          
  
  Hospitalized 
 
135 (26.6) 
 
130 (25.6) 
 
p<0.00
1 
 
153(30.1) 
 
p<0.00
1 
  
  Home-quarantined 
 
40 (7.9) 
 
153 (30.1) 
  
168 (33.1) 
 
  
                          
Statistical tests were used as appropriate (T-test, Chi-squared test) 
* OD vs No dysfunction, and GD vs No dysfunction, respectively 
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Table 4. Clinical Characteristics of Olfactory and Gustatory Dysfunction  
  
     
  
Variable 
 
Olfactory dysfunction 
 
Gustatory dysfunction   
  
  
N=283 
 
N=321   
  
     
  
Degree of dysfunction 
    
  
  Partial 
 
90 (31.8) 
 
118 (36.8)   
  Total 
 
182 (64.3) 
 
193 (60.1)   
  Unable to assess the degree of dysfunction 
 
11 (3.9) 
 
10 (3.1)   
  
     
  
Mean onset ± SD (range) - days  
    
  
  When 1st symptom: time to the 2nd symptom § 
 
4.9 ± 4.3 (1-15) 
 
4.9 ± 4.3 (1-15)   
  When not 1st symptom: time after the 1st symptom # 
 
4.3 ± 2.6 (1-19) 
 
4.3 ± 2.7 (1-19)   
  
     
  
  Cases with complete resolution of the dysfunction 
 
3.3 ± 2.7 (0-10) 
 
3.3 ± 2.8 (0-15)   
  Cases with ongoing dysfunction 
 
3.9 ± 3.2 (0-19) 
 
3.8 ± 3.3 (0-19)   
  
     
  
Mean duration of symptoms ± SD (range) - days  
    
  
  Cases with complete resolution of the dysfunction 
 
9.4 ± 5.1 (2-40) 
 
9.2 ± 5.4 (2-30)   
  Cases with ongoing dysfunction 
 
12.7 ± 7.0 (1-40) 
 
12.4 ± 6.8 (1-36)   
  
     
  
Recovery of symptoms* - no. (%) 
    
  
  Within 14 days 
 
118 (80.3) 
 
143 (80.3)   
  After 14 days 
 
29 (19.7) 
 
35 (19.7)   
  
     
  
§ Patients affected by olfactory and gustatory dysfunction reported these complaints as single first symptom of the infection with SARS-
CoV-2 in 26 cases (5.1%), with a median anticipation of 3 days compared to other symptoms. Isolated dysosmia or isolated dysgeusia have 
not been observed as first symptoms of presentation. 
# Patients affected by olfactory and gustatory dysfunction reported these complains as delayed symptom of presentation of the infection 
with SARS-CoV-2 in 231 (81.6%) and 264 (82.2%) cases, respectively. 
* Only patients who reported complete resolution of olfactory (147) and gustatory (178) dysfunction were considered. 
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Figure 
 
 
Figure 1. Network analysis. Blue and red lines indicate positive and negative inter-
connections, respectively. Thicker lines indicate stronger inter-connections. 
 
 
 
